Theratechnologies responses to current COVID-19 pandemic

Apr 08, 2020

Ensuring patient access and product supply:

  • Theratechnologies Inc. has enough inventory to provide TROGARZO®, EGRIFTA SVTM or EGRIFTA® to existing and new patients for the next 12 months.
  • Production of TROGARZO®, EGRIFTA SVTM or EGRIFTA® has not been affected by the COVID-19 situation.
  • The Department of Health and Human Services (DHHS) issued on Friday March 20, 2020 Interim Guidance for COVID-19 and persons with HIV which can be found HERE. It highlights the need for continuity of care.
  • Our primary objective is to ensure the health of persons with HIV and the continuity of care for any patient in need of TROGARZO®, EGRIFTA SVTM or EGRIFTA® during the COVID-19 period.
    • For persons with advanced or poorly controlled HIV who will be prescribed Trogarzo® during the COVID-19 period, we have implemented measures to ensure that these new patients will be taken care of.
      • If a provider or a person with HIV becomes aware of a need to change infusion location for TROGARZO®, THERA patient support® needs to be informed as soon as possible in order to evaluate what is possible in a timely manner.
    • For persons required to start EGRIFTA SVTM or EGRIFTA® during COVID-19, every step has been taken to assure these new patients will be taken care of.
    • For current TROGARZO®, EGRIFTA SVTM or EGRIFTA® patients, we are fully prepared to support them in light of the COVID-19 situation.
    • Should you have any questions related to TROGARZO®, EGRIFTA SVTM or EGRIFTA®, we are here to help through THERA patient support® (1-833-238-4372, Mon-Fri 8:30AM-8:00PM ET). We provide support from infusion location to insurance coverage and co-pay assistance.
  • Full prescribing information and Important Safety Information about TROGARZO®, EGRIFTA SVTM and EGRIFTA® can be found on and, respectively.

Caring for people living with HIV and our people:

In these unprecedented times, we took several measures to protect the well-being of the communities in which we operate and that of our people. We suspended all face-to-face interactions in clinics, hospitals, Aids services organizations and other offices we interact with on March 16th, 2020.  Virtual interactions have been implemented to continue providing education and support for the people in need of our medications, people living with HIV, case managers, healthcare providers and their staff, on how to manage HIV during the COVID-19 pandemic.